|
Group Members |
|
|
|
·
1994-1999, Ph.D. in Biochemistry, Department of
Biochemistry, Kharkov State University, Kharkov, Ukraine
·
1989-1994, M.S. in Biology, Department of
Biochemistry, Kharkov State University, Kharkov, Ukraine
·
2010-Present, Assistant Research Professor,
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers
University, Piscataway, NJ
·
2008-2010, Research Associate, Department of
Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway,
NJ
·
2006-2008, Postdoctoral Associate, Department of
Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway,
NJ
·
2004-2006, Postdoctoral Associate, Department of
Biochemistry, the Laboratory for Membrane and Liposome Research; Hebrew
University-Hadassah Medical School, Jerusalem, Israel.
·
2000-2004, Scientist, Department of Biochemistry,
the Laboratory for Membrane and Liposome Research; Hebrew University-Hadassah
Medical School, Jerusalem, Israel.
·
Delivery of drugs, antisense oligonucleotides and
siRNA for cancer treatment and imaging
·
Drug Delivery and Translational Research
Outstanding Research Paper Award for Year 2011 (S. Betigeri,
O. Garbuzenko, T. Minko), 2012.
·
Rutgers 2012 Most Innovative Technology Award (T.
Minko, O. Garbuzenko, M. Zhang, L, Rodriguez),
2012.
·
Controlled Release Society Outstanding
Pharmaceutical Paper Award, (O. Taratula, M. Shah, O.
Garbuzenko, T. Minko), 2011.
·
Gallo Award for Scientific Excellence, The Cancer
Institute of New Jersey for Outstanding Cancer Research (O. Garbuzenko, O. Taratula, T.
Minko), 2011.
·
The paper O. B. Garbuzenko,
M. Saad, V. P. Pozharov, K.
R. Reuhl, G. Mainelis, T.
Minko. Inhibition of lung tumor growth by complex pulmonary delivery of drugs
with oligonucleotides as suppressors of cellular resistance, Proc. Natl. Acad.
Sci. USA, 107, 10737-10742 (2010) was highlighted in PNAS Media Selections; EurekAlert!; DOTMED NEWS; NewScientist Magazine; Ecancermedicalscience.
·
Controlled Release Society Outstanding
Pharmaceutical Paper Award, (O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, T.
Minko), 2010.
·
First Place Poster Award, The
Biennial New Jersey Pharmaceutical Conference (M. Zhang, O. Garbuzenko, L. Rodriguez, T. Minko), 2009.
·
Second Place Poster Award, The
Biennial New Jersey Pharmaceutical Conference (O. Taratula,
O. Garbuzenko, Z. Wang, G. Mainelis,
T. Minko), 2009.
·
The New Jersey Cancer Research Award for Scientific
Excellence (O. Taratula, O. B. Garbuzenko,
R. Savla, H. He, T. Minko), 2009.
·
The paper M. Saad, O.
B. Garbuzenko, T. Minko, Co-delivery of siRNA and
an anticancer drug for treatment of multidrug resistant cancer, Nanomedicine,
3, 761-776 (2008) was highlighted in LeadDiscovery
(http://www.leaddiscovery.co.uk/articles/19025451/ dailyupdate).
·
The paper "Receptor targeted polymers,
dendrimers, liposomes: Which nanocarrier is the most efficient for
tumor-specific treatment and imaging?", J.
Control. Release, 130, 107-114, 2008 (M. Saad, O.
B. Garbuzenko, E. Ber,
P. Chandna, J. J. Khandare,
V. P. Pozharov, T. Minko) was highlighted in Cover
Story by the Editor-in-Chief of the Journal (K. Park, J. Control. Release, 130,
139, 2008) and the figure from the paper was selected for the cover page of the
issue.
·
Controlled Release Society Outstanding
Pharmaceutical Paper Award, 2008 (S. Betigeri, O.
B. Garbuzenko, T. Minko).
1. Nanotechnology Approach for Inhalation Therapy. Contributors: T. Minko, O. Garbuzenko, V. Ivanova, Patent number US 9,445,993 B2, Date of Patent Sep. 20, 2016.
2. Compositions and methods for delivering nucleic acid molecules and treating cancer. Contributors: T. Minko, L. Rodriguez-Rodriguez, O. B. Garbuzenko, O. Taratula, Patent number US 9,289,505 B2, Date of Patent Mar. 22, 2016.
3. E2F as a Target of Hormone Refractory Prostate Cancer. Contributors: J. R. Bertino, D. Banerjee, T. Minko, O. B. Garbuzenko, X. Xie, J. E. Kerrigan, E. E. Abali, K. W. Scotto, US 9,314,497 B2, Date of Patent Apr. 19, 2016.
4. E2F as a Target of Hormone Refractory Prostate Cancer. Contributors: J. R. Bertino, D. Banerjee, T. Minko, O. B. Garbuzenko, X. Xie, J. E. Kerrigan, E. E. Abali, K. W. Scotto, US 8,822,421 B2, Date of Patent Sep. 3, 2014.
1.
O.
B. Garbuzenko, V. Ivanova,
V. Kholodovych, D. C. Reimer, K. R. Reuhl, E. Yurkow, D. Adler, T.
Minko, Combinatorial treatment of idiopathic pulmonary fibrosis using
nanoparticles with prostaglandin E and siRNA(s), Nanomedicine, 13, 1983-1992
(2017).
2.
M. Dorrani, O. B. Garbuzenko,
T. Minko, B. Michniak-Kohn, Development of
Edge-activated liposomes for siRNA delivery to human basal epidermis for
melanoma therapy, J Control Release, 228,150-158 (2016).
3.
P. T. Yin, S. Shah, N. J. Pasquale, O. B. Garbuzenko,
T. Minko, K-B. Lee, Stem cell-based gene therapy activated using magnetic hyperthermia
to enhance the treatment of cancer, Biomaterials, 81:46-57 (2016).
4.
L. Y. Peddada, O. B. Garbuzenko,
D. I. Devore, T. Minko, C. M. Roth, Delivery of antisense oligonucleotides
using poly(alkylene oxide)-poly(propylacrylic
acid) graft copolymers in conjunction with cationic liposomes, J Control
Release. 194C, 103-112 (2014).
5.
R. Savla, O. B. Garbuzenko,
S. Chen, L. Rodriguez-Rodriguez, T. Minko, Tumor-targeted responsive
nanoparticle-based systems for magnetic resonance imaging and therapy, Pharm Res,
31(12), 3487-3502 (2014).
6.
X. Xie, N. Bansal, T.
Shaik, J. E. Kerrigan, T. Minko, O. Garbuzenko, E. E. Abali, N.
Johnson-Farley, D. Banerjee, K. W. Scotto, J. R. Bertino,
A novel peptide that inhibits E2F transcription and regresses prostate tumor
xenografts, Oncotarget, 5, 901-907 (2014).
7.
O.
B. Garbuzenko, G. Mainelis,
O. Taratula, T. Minko, Inhalation treatment of lung
cancer: the influence of composition, size and shape of nanocarriers on their
lung accumulation and retention, Cancer Biol Med,
11(1) 44-55 (2014).
8.
O.
B. Garbuzenko, J. Winkler, M. S. Tomassone, T. Minko, Biodegradable janus nanoparticles for local pulmonary delivery of
hydrophilic and hydrophobic molecules to the lungs, Langmuir, 30(43),
12941-12949 (2014).
9.
L. Y. Peddada, O. B. Garbuzenko,
D. I. Devore, T. Minko, C. M. Roth, Delivery of antisense oligonucleotides
using poly(alkylene oxide)-poly(propylacrylic
acid) graft copolymers in conjunction with cationic liposomes, J Control
Release. 194C, 103-112 (2014).
10.
R. Savla, O. B. Garbuzenko,
S. Chen, L. Rodriguez-Rodriguez, T. Minko, Tumor-targeted responsive
nanoparticle-based systems for magnetic resonance imaging and therapy, Pharm
Res, 31(12), 3487-3502 (2014).
11.
X. Xie, N. Bansal, T.
Shaik, J. E. Kerrigan, T. Minko, O. Garbuzenko, E. E. Abali, N.
Johnson-Farley, D. Banerjee, K. W. Scotto, J. R. Bertino,
A novel peptide that inhibits E2F transcription and regresses prostate tumor
xenografts, Oncotarget, 5, 901-907 (2014).
12.
O. Taratula, A. Kuzmov, M. Shah, O. B. Garbuzenko,
T. Minko, Nanostructured lipid carriers as multifunctional nanomedicine
platform for pulmonary co-delivery of anticancer drugs and siRNA, J Control
Release, 171, 349-357 (2013).
13.
G. Mainelis, S. Seshadri, O. B. Garbuzenko,
Z. Wang, T. Minko, Characterization and application of a nose-only exposure
chamber for inhalation delivery of liposomal anti-cancer drugs and nucleic
acids to mice, J Aerosol Med Pulm Drug Deliv, 26(6), 345-354 (2013).
14.
V. Ivanova, O. B. Garbuzenko, K. R. Reuhl, T.
Minko, Inhalation Treatment of Pulmonary Fibrosis by Liposomal Prostaglandin
E2, Eur J Pharm Biopharm,
84, 335-344 (2013).
15.
V. Shah, O. Taratula, O.
B. Garbuzenko, M. L. Patil,
R. Savla, M. Zhang, T. Minko, Genotoxicity of
nanocarriers with different composition, architecture, size, molecular weight
and charge, Current Drug Discovery Technologies, 10, 8-15 (2013).
16.
M. Zhang, O. B. Garbuzenko,
K. R. Reuhl, L. Rodriguez-Rodriguez, T. Minko, Two-in-one: combined targeted chemo and gene therapy for
tumor suppression and prevention of metastases, Nanomedicine (Lond), 7, 185-197 (2012).
17.
O. Taratula, O. B. Garbuzenko, A. M. Chen, T. Minko, “Innovative strategy
for treatment of lung cancer: targeted nanotechnology-based inhalation
co-delivery of anticancer drugs and siRNA, J. Drug Target., 19, 900-914 (2011).
18.
R. Savla, O. Taratula, O. B. Garbuzenko,
T. Minko, Targeted, pH-sensitive quantum dot delivery of doxorubicin for
treatment of ovarian cancer, J. Control. Release, 2011, 153, 16-22.
19.
M. L. Patil, M. Zhang, O.
B. Garbuzenko, T. Minko, Multifunctional triblock
nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular delivery of siRNA
and potent gene silencing, ACS Nano, 5, 1877-1887 (2011).
20.
S. Betigeri, M. Zhang, O.
Garbuzenko, T. Minko, Non-viral delivery of siRNA
or antisense oligonucleotides targeted to Jun N-Terminal Kinase 1 prevents
cellular hypoxic damage, Drug Deliv. and Transl. Res., 1, 13-24 (2011).
21.
O. B. Garbuzenko,
M. Saad, V. P. Pozharov, K.
R. Reuhl, G. Mainelis, T.
Minko. New horizons in treatment of lung cancer: Combinatorial local inhalatory delivery of drugs and suppressors of cellular
resistance, Proc. Natl. Acad. Sci. USA, 107, 10737-10742 (2010).
22.
D. A. Christian, O. B. Garbuzenko,
T. Minko, D. E. Discher, Polymer Vesicles with a Red
Cell-like Surface Charge: Microvascular imaging and in vivo Tracking with
Near-Infrared Fluorescence, Macromol. Rapid Commun.,
31, 135-141 (2010).
23.
O. Taratula, O Garbuzenko,
P. Kirkpatrick, I. Pandya, R. Savla, V. Pozharov, H. He, and T. Minko.
Surface-engineering targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery, J. Control. Release, 2009,
140:284-293.
24.
D. Christian
, S. Cai , O. Garbuzenko,
T. Harada, A. Zajac, T. Minko and D. Discher, Flexible
filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor
shrinkage, Mol. Pharmaceutics, 2009 6:1343-1352.
25.
O. B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A. A. Vetcher,
V. A. Soldatenkov, D. C. Reimer, T. Minko, Intratracheal versus intravenous liposomal delivery of
siRNA, antisense oligonucleotides and anticancer drug, Pharm. Research, 2009,
26 (2):382-94.
26.
M. L. Patil, M. Zang, O. Tarantula, O.
Garbzuenko, H. He, T. Minko. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery:
effect of the degree of quaternization on cancer
targeting, Biomacromolecules, 2009, 10(2):258-66.
27.
Kizelsztein
P, Ovadia H, Garbuzenko O, Sigal A, Barenholz Y. Pegylated nanoliposomes
remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis.
Journal of Neuroimmunology, 2009, 213(1-2):20-5.
28.
M. Saad, O. B. Garbuzenko, T.
Minko, Co-delivery of siRNA and an anticancer drug for treatment of multidrug
resistant cancer, Nanomedicine, 2008, 3(6):761-76.
29.
M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov, T.
Minko, Receptor - targeted nanocarriers for tumor specific treatment and
imaging, J. Control. Release, 2008, 130(2):107-14.
30.
Y. Wang, M. Saad, R. I. Pakunlu, J. J. Khandare, O. B. Garbuzenko, A.
A. Vetcher, V. A. Soldatenkov,
V. P. Pozharov, T. Minko, Non-viral nanoscale-based
delivery of antisense oligonucleotides targeted to HIF1 alpha enhances the
efficacy of chemotherapy in drug resistant tumor, Clin.
Cancer Res., 2008, 14(11): 3607-16.
31.
T. Minko, J. J. Khandare,
A. A. Vetcher, V. A. Soldatenkov,
O. B. Garbuzenko,
M. Saad, V. P. Pozharov,
Multifunctional nanotherapeutics for cancer (Chapter
10), In.: Multifunctional Pharmaceutical Nanocarriers, V. P. Torchilin, Ed., Springer, 2008, pp. 309-335.
32.
V. Wasserman, P. Kizelsztein, O. Garbuzenko, R. Kohen, H. Ovadia,
R. Tabakman
and Y. Barenholz. The antioxidant Tempamine (TMN): in vitro proapoptotic
and neuroprotective effects and optimization of liposomal encapsulation,
Langmuir, 2006, 13;23(4):1937-47.
33.
Garbuzenko O., Zalipsky S., Qazen M., Barenholz Y., Electrostatics of PEGylated micelles and liposomes
containing charged and neutral lipopolymers. Langmuir. 2005, 15; 21(6): 2560-8.
34.
Garbuzenko O., Barenholz Y., Priev A. Effect of grafted PEG on
liposome size and on compressibility and packing of lipid bilayer.
Chem Phys Lipids. 2005: 135 (2): 117-29.
35.
A.E.Kuzmis, O.B.Garbuzenko,
A.V. Naglov, T.U. Maistrenko,
E.E.Persky. Effect of Ca2+
and chlorpromazine on collagen synthesis
and processing in rats aorta and skin in vitro, Biology Vestnik,
2001, 5(1-2):100-2.
36.
O.B.Garbuzenko, E.E Persky. The
influence of cooling on the collagen and elastine
exchange in rats skin in vitro// The problems of
Cryobiology, 1998.
37.
E.Persky, I.V.Kuznetsov, O.B.Garbuzenko The temperature effect of some stages of rat skin
collagen exchange in vitro// Reports of the National Academy of Science,
Ukraine, 1997.
38.
O.B. Garbuzenko, I.V.Kuznetsov, A.V. Naglov, N.A. Nikitina, E.E. Persky,
L.A. Utevskaya Structural and metabolic mechanisms of
collagen adaptation to endogenous and exogenous factors effects// School of
Fundamental Medicine Journal, 1997.
39. I.V.Kuznetsov, O.B.Garbuzenko, A.E.Kuzmis, N.A.Nikitina, E.E.Persky, L.A.Utevskaya Peculiar features of collagen exchange in
skin of vertebrata animals during temperature adaptation// the problems of
Cryobiology, 1997.
· Ph.D in Biology - Cytology, Moscow State University, Russia
· M. S. in Biology - Genetics, Kiev State University, Kiev, Ukraine.
· 2014 – Present, Professional/Research/Manager Casual, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ
· 2011 – 2014, Research Associate – Department of Plant Biology and Pathology, Rutgers University, New Brunswick, NJ
· 2003 – 2010 Research Assistant Professor –Department of Cancer Biology Thomas Jefferson University, Philadelphia, PA
· 1996 – 2003, Senior Research Scientist - BASF Plant Science L.L.C., NC, USA (formerly American Cyanamid Company, USA)
· 1981 – 1996, Research Scientist, Senior Scientist – Institute of Cell Biology and Genetic Engineering, Kiev, Ukraine
· 1977 – 1981, Post -Graduate Student - Institute of Molecular Biology, Moscow, Russia
Mammalian cell
tissue culture technologies, cultivation of different human cell lines,
mouse/rat cell lines, cancer cells, enucleation of mammalian cells, cell fusion
technologies, production of hybrids, hybridomas
producing anti-cancer monoclonal antibodies, anti-rabies monoclonal antibodies,
animal surgery, isolation of lymphocytes and peritoneal cells, production of
recombinant vaccines and microbicides and testing them in animal models, evaluation
of the toxicity to mammalian cells of plant extracts, testing of plant
preparations in vitro and in vivo, development of cell suspension bioreactor
for large scale production of pharmaceuticals.
Standard molecular
biology techniques, isolation of plasmid DNA, PCR, Western blot analysis,
ELISA, enzyme assays, staining techniques, light microscopy, fluorescent
imaging technology, immunofluorescent staining, green fluorescent protein and
luciferase reporter assays, chromosomal analysis, autoradiography, flow cytometry.
Plant propagation
by tissue culture, establishment of cell suspensions, in vitro
regeneration, embryogenesis; cultivation
of protoplasts, cell fusion and production of plant hybrids, mutagenesis by
UV-radiation/NMU/EMS; transformation of plants by Agrobacterium, particle
bombardment, electroporation of protoplasts,
plastid transformation, transient expression, maintenance of plants in
greenhouse, evaluation of mutant and transgenic plants for herbicide
resistance, field trials.
· 2014 – 2015, Improved lettuce varieties for enhanced metabolic resiliency, Botanical Research Center Pilot Project. Role – PI
· Pogrebnyak N., Andrianov V., Golovkin M. Methods and compositions for production of recombinant pharmaceutical proteins in medicinal plants (2014) WO 2014055659 A1
· Raskin I., Cheng D., Pogrebnyak N. Red lettuce with increased anthocyanins, polyphenols, and oxygen radical absorption capacity.( 2012) US Provisional Patent Application No 61/651,122
· Koprowski H., Golovkin M., Pogrebnyak N. Uses of Yerba Santa. (2012) US 8,148,609 B2
· Zhen R-G, Hirayama L., Peng J., Pogrebnyak N., Carpenter B., Cozzitorto J., Brown K., Hedrick J., Stahl J. Carotenoid biosynthesis inhibitor resistance genes and methods of use in plants. WO/2005/111218
1. D.M.Cheng, N. Pogrebnyak, P.Kuhn, C.G.Krueger, W.D.Johnson, I.Raskin. Development and phytochemical characterization of high polyphenol red lettuce with anti-diabetic properties. PLOS ONE, 2014, Vol. 9, No. 3, article e91571.
2. D. M. Cheng, N. Pogrebnyak, P. Kuhn, A. Poulev, C. Waterman, P. Rojas-Silva, W. D. Johnson, and I. Raskin.Polyphenol-rich Rutgers Scarlet Lettuce improves glucose metabolism and liver lipid accumulation in diet induced obese C57BL/6 Mice. Nutrition, 2014, Vol. 30, pp.S52-S58.
3. Grace, M., Guzman, I., Roopchand, D., Moskal, K., Cheng, D., Pogrebnyak N., Raskin, I., Howell, A., and M. A. Lila. Stable binding of alternative protein-enriched food matrices with concentrated cranberry bioflavonoids for functional food applications. J. Agric. Food Chem., Vol. 61, No. 28, pp. 6856-6864, 2013.
4. Andrianov V., Borisyuk N., Pogrebnyak N., Brinter A., Dixon J., Spitsin S., Matyszczuk P, Flynn J., Laurelli L., Andruszak K., Golovkin M., and Koprowski. Potential of tobacco as a production platform for biofuel: over-expression of Arabidopsis DGAT and Lec2 genes increases accumulation and shifts the composition of lipids in green biomass. Plant Biotechnology Journal, 2010, v 8, p. 277-287.
5. Brodzik R., Spitsin S., Pogrebnyak N., Andruszhak K., Bandurska K., Koprowski H., Golovkin M. Generation of Plant-derived Recombinant DTP Subunit Vaccine. Vaccine, 2009, v 27, p.3730-3734.
6. Spitsin S., Andrianov V., Pogrebnyak N., Smirnov Y., Borisjuk N, Portocarrero C., Veguilla V., Koprowski H., Golovkin M. Immunological Assessment of plant-derived Avian Flu H5/HA1 Variants. Vaccine, 2009, 27, 1289-1292.
7. Bandurska K., Brodzik R., Spitsin S., Kohl T., Portocarrero C., Smirnov Y., Pogrebnyak N., Sirko A., Koprowski H., Golovkin M. Plant-produced Hepatitis B Core Protein Chimera Carrying Anthrax Protective Antigen Domain-4. Hybridoma, 2008, 27(4), p.241-247.
8. Golovkin M., Spitsin S., Andrianov S., Smirnov Y., Xiao Y., Pogrebnyak N., Markley K., Brodzik R., Gleba Y., Isaacs S. and Koprowski H. Smallpox subunit vaccine candidate produced in plants confers protection in mice. Proc. Natl. Acad. Sci. USA, 2007, v 104, no 16, p.6864-6869.
9. Pogrebnyak N., Markley K., Smirnov Y., Bandurska K., Koprowski H. and Golovkin M. Collard and cauliflower as a base for production of recombinant antigens. Plant Science, 2006, v 171, issue 6, p.677-685.
10. Brodzik R., Glogowska M., Bandurska K., Okulicz M., Deka D., Ko K., Linden J., Leusen J., Pogrebnyak N., Golovkin M., Steplewski Z. and Koprowski H. Plant-derived anti-Lewis Y monoclonal antibody exhibits biological activities for efficient immunotherapy against human cancer cells. Proc. Natl. Acad. Sci. USA, 2006, v 103, no 23, p.8804- 8809.
11. Pogrebnyak N., Golovkin M., Andrianov V., Spitsin S., Smirnov Y., Egolf R. and Koprowski H. SARS spike protein production in plants: development of recombinant vaccine. Proc. Natl. Acad. Sci. USA, 2005, v 102, no 25, p.9062-9067.
12. A.E.Golovko, N.Ya.Pogrebnyak, M.A.Bannikova. Cultivation in vitro and transformation of sugar beet. Physiology and biochemistry of cultivated plants, 2002, 34, N5 (199), p 394-405.
13. N. Pogrebnyak, E.N.Shisha, S.V.Storozhenko, L.I.Yuzefovich, B.Diettrich and Y.Y.Gleba. Genetic transformation of Digitalis purpurea by Agrobacterium tumefaciens. Biopolymers and the Cell, 1997, v 13, N2, p. 60-62.
14. J.G.Schaart, K.J.Puite, L.Kolova and N.Pogrebnyak. Some methodological aspects of apple transformation by Agrobacterium. Euphytica, 1995, 85, p. 131-134.
15. S.V.Storozhenko, O.A.Kravets, N.Ya.Pogrebnyak, Y.Y.Gleba. Isolation of the transgenic potato plants expressing the mutant acetolactate synthase gene of Arabidopsis thaliana. Biopolymers and the Cell, 1994, v. 10, p. 67-72.
16. O.A.Kravets, N.Pogrebnyak. E.N. Shisha, S,V, Lopato, Y.Y. Gleba. Transformation of different potato cultivars and analysis of the transgenic plants. Biopolymers and the Cell. 1992, v.8, N6, p. 44-48.
17. S.G.Kushnir, L.R.Shlumukov, N.Ya.Pogrebnyak, S.Berger, Y.Y.Gleba. Functional cybrid plants possessing a Nicotiana genome and an Atropa plastome. Mol.Gen.Genet., 1987, 209, p.159-163.
18. S.G.Kushnir, L.R.Shlumukov, N.Ya.Pogrebnyak, Y.Y.Gleba.Cell-engineered synthesis of cybrids containing a Nicotiana nucleus and Atropa belladonna plastids. Proc.Acad.Sci.USSR, 1986, 291, p.1238-1240.
19. N.Ya Pogrebnyak, A.A.Kushch, A.V.Zelenin.Lymphocytes in the heterokaryons enter the S-phase independently from cell tissue proliferating activity. Proc.Acad.Sci.USSR, 1982, 266, p.478-481.
20. A.A.Kushch, N.Ya.Pogrebnyak, I.P.Diskant. Use of heterokaryons for determing ability of nonproliferating cells enter the S-phase of cell cycle. Cytology, 1981, 23, p.1206-1209.
21. N.Ya Pogrebnyak, V.A.Polunovsky, A.A.Kushch, A.V. Zelenin. Different extent of peritoneal cell nuclei reactivation in heterokaryons with dormant, proliferation-stimulated and constantly proliferating cells. Proc.Acad.Sci.USSR, 1981, 258, p.1220-1224.
1. J. Sapiezynski, O. Taratula, L. Rodriguez-Rodriguez, T. Minko, Precision targeted therapy of ovarian cancer, J Control Release, 243, 250-268 (2016).